Literature DB >> 16279149

The use of systematic reviews when designing studies.

Nicola J Cooper1, David R Jones, Alex J Sutton.   

Abstract

BACKGROUND: The importance of systematic reviews in identifying gaps in the evidence base and providing a quantitative basis for informing new research initiatives is widely acknowledged, but little is known about what actually happens in practice. Our objective was to assess the use made of results of reviews in the designing of new studies.
METHODS: Of all Cochrane reviews published in 1996, those updated in 2002 or 2003 were identified. Authors of trials added in the updates were contacted and asked if use had been made of the 1996 Cochrane or other reviews in designing their study.
RESULTS: Of 32 authors of studies newly included in 33 Cochrane reviews which met our inclusion criteria, 24 (75%) responded. Eleven (46%) respondents were aware of the relevant Cochrane review at the time they designed their study. In eight (33%) cases the design of the new study had been influenced by a review; in two (8%) this was the relevant Cochrane review.
CONCLUSIONS: Cautious interpretation of these results is necessary, but it is apparent that the proportion of study investigators using Cochrane or other systematic reviews in designing their new studies was very limited. Inclusion of encouragement in publication or application guidelines to consider and cite review results is desirable.

Mesh:

Year:  2005        PMID: 16279149     DOI: 10.1191/1740774505cn090oa

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  28 in total

1.  Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report.

Authors:  Mike Clarke; Sally Hopewell; Iain Chalmers
Journal:  J R Soc Med       Date:  2007-04       Impact factor: 5.344

2.  [Systematic reviews and meta-analyses in surgery].

Authors:  M K Diener; C M Seiler; G Antes
Journal:  Chirurg       Date:  2007-10       Impact factor: 0.955

3.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

4.  Comparator bias: why comparisons must address genuine uncertainties.

Authors:  Howard Mann; Benjamin Djulbegovic
Journal:  J R Soc Med       Date:  2013-01       Impact factor: 5.344

5.  Doing clinical trials large enough to achieve adequate reductions in uncertainties about treatment effects.

Authors:  Michael J Campbell
Journal:  J R Soc Med       Date:  2013-02       Impact factor: 5.344

6.  Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.

Authors:  E Boettcher; G Csako; F Pucino; R Wesley; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2011-11-04       Impact factor: 8.171

7.  Poorly cited articles in peer-reviewed cardiovascular journals from 1997 to 2007: analysis of 5-year citation rates.

Authors:  Isuru Ranasinghe; Abbas Shojaee; Behnood Bikdeli; Aakriti Gupta; Ruijun Chen; Joseph S Ross; Frederick A Masoudi; John A Spertus; Brahmajee K Nallamothu; Harlan M Krumholz
Journal:  Circulation       Date:  2015-03-26       Impact factor: 29.690

8.  Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis.

Authors:  Rohit Loomba; Robert Wesley; Andrew Bain; Gyorgy Csako; Frank Pucino
Journal:  Clin Gastroenterol Hepatol       Date:  2008-12-27       Impact factor: 11.382

9.  The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials.

Authors:  Ashley P Jones; Elizabeth Conroy; Paula R Williamson; Mike Clarke; Carrol Gamble
Journal:  BMC Med Res Methodol       Date:  2013-03-25       Impact factor: 4.615

Review 10.  The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trial.

Authors:  Carrol Gamble; Andrew Wolf; Ian Sinha; Catherine Spowart; Paula Williamson
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.